Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

April 15, 2024

https://www.globenewswire.com/news-release/2024/04/15/2862776/0/en/Atossa-Therapeutics-and-Quantum-Leap-Healthcare-Announce-I-SPY-2-Clinical-Trial-to-Evaluate-Z-Endoxifen-in-Combination-with-Abemaciclib-VERZENIO-in-Women-with-ER-HER2-Breast-Cancer.html

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.